食物アレルギーのマウスアナフィラキシー性血圧降下検査法での誘発行程の改良

書誌事項

タイトル別名
  • Improved Mouse Anaphylactic Hypotension Testing for Food Allergens by Intraperitoneal Administration
  • ショクモツ アレルギー ノ マウスアナフィラキシーセイ ケツアツ コウカ ケン

この論文をさがす

抄録

Previously, we proposed a standard concept for quantification of the intensities of mouse anaphylactic responses using fall in blood pressure (mouse anaphylactic hypotension test; MAHT) after treatment with food allergens. In the present study, optimal rout for elicitation of an anaphylactic response in the MAHT were examined with comparison of intravenous (i.v.) and intraperitoneal (i.p.) administrations. Since only water-soluble fractions were appropriate for i.v. administration, food samples were extracted with three kinds of buffers at different pHs. The water-insoluble fractions which could not be extracted in this way, therefore could not be assessed for allergenicity. In contrast, whole food samples could be administered i.p. in saline. To determine whether i.p. administration was appropriate to detect allergenicities, several standard antigens such as hen egg-white lysozyme, ovalbumin and ovomucoid were tested. All looked similar response to i.v. administration (Fig. 3). Further examination of foodstuffs known to be potent allergens in man, including egg-white (raw, boiled), skimmed milk, mackerek, soybean, wheat flour, rice and buchwheat gave clear positive results, the response to i.p. administration in challenge often being greater than that observed with i.v. administration. This was especially the case with wheat flour, rice and buckwheat samples (Fig. 6). In addition i.p. administration allowed easy quantification of allergic intensity of water-insoluble substances which could not be tested by the i.v. route. In summary, by applying i.p. route of administration, allergenicity of whole food samples, including water-insoluble fractions in saline, could be detected. Accordingly, this very simple and rapid method can be recommended for administering samples for challenge tests.

収録刊行物

参考文献 (7)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ